Acurx Pharmaceuticals (ACXP) investor relations material

Company overview and business model

• Late-stage biopharmaceutical company developing small molecule antibiotics targeting difficult-to-treat Gram-positive bacterial infections, including priority pathogens identified by WHO, CDC, and FDA.

• Pipeline includes candidates for Clostridioides difficile, MRSA, VRE, drug-resistant Streptococcus pneumoniae, and anthrax.

• Focus on inhibiting DNA polymerase IIIC to induce bacterial cell death.

• Organized in Delaware in 2017, converted to a corporation in 2021.

Financial performance and metrics

• As of June 30, 2026, net tangible book value was $8.2 million ($1.74 per share).

• After offering, adjusted net tangible book value would be $10.3 million ($1.66 per share), with immediate dilution of $0.08 per share to existing stockholders.

• Never declared or paid cash dividends; intends to retain earnings.

Use of proceeds and capital allocation

• May receive up to $2.8 million in gross proceeds from sales to Lincoln Park under the Purchase Agreement, in addition to $9.2 million previously received.

• Proceeds intended for working capital and general corporate purposes, including R&D and administrative expenses.

• Management has broad discretion over use of proceeds.